Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Keratinocyte-conditioned media of resting, IL-17A-, and/or transforming growth factor-β-primed primary keratinocytes were used to stimulate healthy donors and scleroderma fibroblasts.
|
31276679 |
2020 |
Systemic Scleroderma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Thal treatment: (a) reduced skin, and pulmonary tissue fibrosis, inflammation score, and hydroxyproline content (P < .001) in BLM-induced SSc mice; (b) reduced the percentages of Th17 cells and associated interleukin (IL)-17A expression (both P < .05) but increased the percentages of Treg cells and its transcription factor Foxp3 expression (both P < .05); (c) correlation analysis found positive correlations between Th17/Treg ratio, the inflammatory score of the skin and pulmonary tissues, hydroxyproline content, and type I collagen messenger RNA expression (r = .8546, .8656, .6902, .6807, .8118, and .8424, respectively, P < .01); (d) Thal inhibited TGF-β1 expression and Smad3 phosphorylation (both P < .05); (e) TGF-β1 was positively correlated with the IL-17A and Th17/Treg ratio (r = .5856, P = .005; r = .6684, P = .0107, respectively).
|
31840939 |
2020 |
Systemic Scleroderma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A significant increase in TH17 cells attested by an increase of RORγT, IL17A mRNA and CD4+ IL17A+ cell was observed in patients with SSc.
|
31776424 |
2019 |
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
No difference was found between patients with SSc and the control group as regards the serum concentration of IL-17A.
|
31110538 |
2019 |
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Among T cells, IL-17-producing helper T (Th17) cell and regulatory T (Treg) cell subsets have recently been found to play crucial roles in SSc pathogenesis.
|
30219674 |
2018 |
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Further in vitro/ex vivo models with human tissues are being developed to investigate the real effect of IL-17 on extracellular matrix deposition, since agents blocking IL-17 are available for the clinic and it will be important to know whether their use in SSc would be beneficial or detrimental.
|
28919455 |
2018 |
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
IL-17A or TGF-β enhanced the production of IL-6 by 8- to 16-folds when compared to control in healthy donors (HD) and SSc cultures.
|
30150989 |
2018 |
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Th17 cells and their signature cytokine IL-17 are also present in salivary gland lesions of primary Sjögren's syndrome (pSS) patients and can be elevated in their peripheral blood.
|
29191572 |
2018 |
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The purpose of this study was to investigate whether IL-17 plays a pathophysiological role in SSc in two different murine models of SSc.
|
30042768 |
2018 |
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
There was no significant difference in serum levels of TNF-α, IFN-γ and IL-17 between the PSS and control groups (Pc > 0.12).
|
28384257 |
2017 |
Systemic Scleroderma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Recently, several articles described that Th17 cells, IL-23 and IL-17 levels were significantly elevated in the peripheral blood or fibrotic sites of SSc.
|
28422002 |
2017 |
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
IL-10-producing regulatory B cells (B10 cells), IL-17+ T cells and autoantibodies in systemic sclerosis.
|
28502678 |
2017 |
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Since the IL-23/IL-17 pathway is known to associate with other autoimmune disease, including rheumatoid arthritis and systemic sclerosis, we hypothesised that IL23R could be a shared susceptibility gene.
|
25858864 |
2015 |
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Th17 cell numbers were elevated in SSc, FoxP3(low)CD45RA(-) T cells produced IL-17, confirming their Th17 potential, which was consistent with the elevated levels of FoxP3(+)IL-17(+) cells in SSc.
|
23776439 |
2013 |
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
IL-17A induces endothelial inflammation in systemic sclerosis via the ERK signaling pathway.
|
24376862 |
2013 |
Systemic Scleroderma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Increased IL-17A levels in the sera and involved skin of SSc may be due to negative feedback.
|
22403442 |
2012 |
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Since the IL-23/IL-17 pathway is known to associate with other autoimmune diseases, including rheumatoid arthritis (RA) and systemic sclerosis (SSc), we hypothesised that IL-23R could be a shared susceptibility gene.
|
17606463 |
2008 |
Systemic Scleroderma
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
Clinical association of serum interleukin-17 levels in systemic sclerosis: is systemic sclerosis a Th17 disease?
|
18329249 |
2008 |
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results suggest that IL-17 overproduction plays an important role in the pathogenesis of SSc, especially in the early stages of the disease, by inducing the proliferation of fibroblasts and the production of IL-1 and the expression of adhesion molecules on endothelial cells.
|
11083268 |
2000 |